Lewy Body Dementia clinical trials
38 active trials name this condition. Describe your situation to see which ones look like a fit.
By location
- Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis
- Comparing Antipsychotic Medications in LBD Over Time
- A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
- Pulsed Electromagnetic Field Treatment With Dementia Patients
- Delirium in Neurodegenerative Disease Patients: A Music Therapy Intervention for Hospital Care
- Neurologic Stem Cell Treatment Study
- 18F-mFBG Cardiac Uptake With Lewy Body Dementia
- PET Tau - Neurodegenerative Disease Imaging
- Low-Dose Radiotherapy for Alzheimer's Disease
- A Study of Neurodegeneration and Neuronal Fluctuations in Lewy Body Disease and Alzheimer's Disease
- Parkinson's Disease Biomarkers in Nerve Cells in the Gut
- Parkinson's Disease and Movement Disorders Clinical Database
- Late Onset Alzheimer's Disease
- Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
- NYSCF Scientific Discovery Biobank
- UPenn Observational Research Repository on Neurodegenerative Disease
- DC Longitudinal Study on Aging and Specimen Bank
- Retinal Imaging in Neurodegenerative Disease
- Modifiable Variables in Parkinsonism (MVP)
- Natural History Study of Synucleinopathies
- Telehealth in Lewy Body Dementia
- PET Imaging Evaluation of [11C]SY08
- Identification of Prodromal Neurodegeneration in Serotonergic-Induced REM Sleep Behavior Disorder
- [18F]F-DOPA Imaging in Patients With Autonomic Failure
- Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases
- Elucidating the Role of Cholinergic Degeneration in Cognitive Fluctuations in Lewy Body Dementia
- Terazosin for Dementia With Lewy Bodies
- Neuromodulation for Behavioral Changes in Neurological Disorders
- VOCALE LBD: Online Peer Support for Caregivers of People With Lewy Body Dementia
- Digital Health Technologies for Progressive Supranuclear Palsy and Dementia With Lewy Bodies
- Alpha-synuclein Education and Disclosure in Individuals With Preclinical and Symptomatic Lewy Body Disease
- Targeting Neuroinflammation as a Contributing Pathology in Alzheimer's Disease Dementia and Related Dementias
- Longitudinal Imaging Biomarkers of Disease Progression in DLB
- MIBG in Aging and Neurologic Disorders
- DaTSCAN Imaging in Aging and Neurodegenerative Disease
- Imaging of Brain Amyloid Plaques in the Aging Population
- Mid-frontal Delta/Theta and Cognitive Control
- North American Prodromal Synucleinopathy Consortium Stage 2
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Lewy Body Dementia” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.